Transplant Tourism and the Traveling Transplant Recipient: Infection Mitigation and Treatment Strategies

Buchan, C. Arianne

doi:10.1007/978-3-030-01751-4_12-1

Table 4 Recommendations for vaccination for hematopoietic stem cell transplant travelers

From: Transplant Tourism and the Traveling Transplant Recipient: Infection Mitigation and Treatment Strategies

Vaccine	Recommendations for adults
Routine immunizations
Parenteral influenza	Yearly Should be considered prior to travel for patients traveling to opposite hemisphere during flu season
Pneumococcal conjugated and polysaccharide	Recommended as part of post-transplant immunization series; booster after 5 years
Tetanus/diphtheria	Recommended as part of post-transplant immunization series; booster every 10 years
Pertussis	Recommended as part of post-transplant immunization series
Hepatitis B	Recommended as part of post-transplant immunization series
Inactivated polio vaccine (IPV)	Recommended as part of post-transplant immunization series
Meningococcal conjugate	Recommended as part of post-transplant immunization series
Measles, mumps, and rubella (MMR)^a	Typically given if serology indicates nonimmune at 24 months post-transplant if patient meets criteria to receive live attenuated vaccine (LAV)^b
Varicella^a	Typically given if serology indicates nonimmune at 24 months post-transplant if patient meets criteria to receive live attenuated vaccine (LAV)^b
Travel immunizations
Hepatitis A	Recommended when indicated
Meningococcal serogroup B	Recommended when indicated
Rabies	Recommended when indicated
Japanese encephalitis (inactivated)	Recommended when indicated
Cholera vaccine	Recommended when indicated; non-live available in Canada and elsewhere; live vaccine contraindicated
Typhim Vi	Recommended when indicated
S. typhi Ty21a^a	Contraindicated; an inactivated vaccine exists and is recommended for these patients
Oral polio vaccine (OPV)^a	Contraindicated; an inactivated vaccine exists and is recommended for these patients
Bacillus Calmette-Guérin (BCG)^a	Contraindicated
Yellow fever vaccine (YFV)^a	Contraindicated, however, may be considered if indicated if patient is 24 months post-transplant and meets criteria to receive live attenuated vaccine (LAV)^b

Adapted from the Centers for Disease Control and Prevention “Recommended Adult Immunization Schedule — United States, 2018,“ [114] “Advising Travelers with Specific Needs: The Immunocompromised Traveler” [43] in Centers for Disease Control and Prevention’s “Health Information for International Travel,” and ASBMT: Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective [29]
^aLive attenuated
^bCriteria to receive LAV: ≥ 24 months post-HSCT, no active GVHD, no immunosuppressive therapy

Back to chapter page

Search

Navigation